Polidocanol for endovenous microfoam sclerosant therapy

Expert Opinion on Investigational Drugs

Volumn 18, Issue 12, 2009, Pages 1919-1927

  Eckmann, David M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Foam; Microfoam; Polidocanol; Sclerosant; Sclerotherapy; Varicose veins

Indexed keywords

CARBON DIOXIDE; PLACEBO; POLIDOCANOL; SURFACTANT; TETRADECYL SULFATE SODIUM; UNCLASSIFIED DRUG; VARISOLVE;

AIR EMBOLISM; ANGIOOSTEOHYPERTROPHY SYNDROME; ARTERIOVENOUS MALFORMATION; BRAIN EMBOLISM; CHEST TIGHTNESS; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG CONTRAINDICATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FOAM; HUMAN; INFLAMMATION; INJECTION SITE PAIN; LEG ULCER; LIQUID; MICROBUBBLE; NEUROLOGICAL COMPLICATION; PATIENT SATISFACTION; REVIEW; SCLEROTHERAPY; SIDE EFFECT; SKIN NECROSIS; SKIN PIGMENTATION; SYSTEMATIC REVIEW; TELANGIECTASIA; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URTICARIA; VARICOSIS; VEIN INSUFFICIENCY; VISUAL DISORDER;

CHEMISTRY, PHARMACEUTICAL; CLINICAL TRIALS AS TOPIC; DOSAGE FORMS; EMBOLISM, AIR; HUMANS; INJECTIONS, INTRAVENOUS; POLYETHYLENE GLYCOLS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; VARICOSE VEINS; VENOUS INSUFFICIENCY;

EID: 72249119277     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903376163     Document Type: Review

References (56)

1. Beebe-Dimmer JL, Pfeifer JR, Engle JS, Schottenfeld D. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 2005;15:175-184
2. Criqui MH, Jamosmos M, Fronek A, et al. Chronic venous disease in an ethnically diverse population: the San Diego population study. Am J Epidemiol 2003;158:448-456 (Pubitemid 37022843)
3. Kundu S, Lurie F, Millward SF, et al. Recommended reporting standards for endovenous ablation for the treatment of venous insufficiency: joint statement of The American Venous Forum and The Society of Interventional Radiology. J Vasc Surg 2007;46:582-589 (Pubitemid 47361633)
4. Mozes G, Kalra M, Carmo M, et al. Extension of saphenous thrombus into the femoral vein: a potential complication of new endovenous ablation techniques. J Vasc Surg 2005;41:130-135
5. Wollmann JC. The history of sclerosing foams. Dermatol Surg 2004;30:694-703
6. Eckmann DM, Kobayashi S, Li M. Microvascular embolization following polidocanol microfoam sclerosant administration. Dermatol Surg 2005;31:636-643
7. Parsi K, Exner T, Connor DE, et al. The lytic effects of detergent sclerosants on erythrocytes, platelets, endothelial cells and microparticles are attenuated by albumin and other plasma components in vitro. Eur J Vasc Endovasc Surg 2008;36:216-223
8. Hamel-Desnos C, Desnos P, Wollmann JC, et al. Evaluation of the efficacy of polidocanol in the form of foam compared with liquid form in sclerotherapy of the greater saphenous vein: initial results. Dermatol Surg 2003;29:1170-1175
9. Cooper WM. Clinical cvaluation of sotradecol, a sodium alkyl sulfate solution, in the injection therapy of varicose veins. Surg Gynencol Obstet 1946;83:647-652
10. Hirschman SR. Sclerosing therapy of varicose veins with sotradecol (sodium tetradecyl sulfate). NY J Med 1947;47:1367-1368
11. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg 2005;31:123-128
12. Min RJ, Khilnani NM. Varicose veins. In: Kandarpa K, editor, Peripheral vascular interventions. 1st edition. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008. p. 417-426
13. Yamaki T. Efficacy of polidocanol-foam compared with polidocanol-liquid in sclerotherapy of venous insufficiency. In: Bergan J, Le Cheng V, editors, Foam sclerotherapy: a textbook. London: Royal Society of Medicine Press, Ltd.; 2008. p. 177-182
14. Wright DD, Gobin JP, Bradbury AW, et al. Polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. In: Bergan J, Le Cheng V, editors, Foam sclerotherapy: a textbook. 1st edition. London: Royal Society of Medicine Press; 2008. p. 105-116
15. European Commission. Opinion on polidocanol (Laureth-9). 2007 Oct 2. Available from: http://ec.europa.eu/health/ph-risk/committees/04-sccp/docs/sccp- o-113.pdf
16. Eichenberger H. Results of the sclerotherapy of varicose veins with hydroxypolyaethoxy-dodecan. Zent Phlebol 1969;8:181-183
17. Rao J, Goldman MP. Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique. Dermatol Surg 2005;31:19-22
18. Tessari L, Cavezzi A, Frullini A. Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatol Surg 2001;27:58-60
19. Frullini A. New technique in producing sclerosing foam in a disposable syringe. Dermatol Surg 2000;26:705-706
20. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA, Redondo P. Treatment of venous malformations with sclerosant in microfoam form. Arch Dermatol 2003;139:1409-16
21. Cabrera J, Redondo P, Beccerra A, et al. Ultrasound-guided injection of polidocanol microfoam in the management of venous leg ulcers. Arch Dermatol 2004;140:667-673
22. Cabrera J, Cabrera J Jr, Garcia-Olmedo MA. Treatment of varicose long saphenous veins with sclerosant in microfoam form: long-term outcomes. Phlebology 2000;15:19-23
23. Hill D. Comparison of sclerosant foam stability by foam composition. Phlebology 2009;24:86
24. Santa Maria N, Eckmann DM. Model predictions of gas embolism growth and reabsorption during xenon anesthesia. Anesthesiology 2003;99:638-645
25. Branger AB, Eckmann DM. Theoretical and experimental intravascular gas embolism absorption dynamics. J Appl Physiol 1999;87:1287-1295
26. Branger AB, Lambertsen CJ, Eckmann DM. Cerebral gas embolism absorption during hyperbaric therapy: theory. J Appl Physiol 2001;90:593-600
27. Drotman RB. The absorbtion, distribution and excretion of alkyl polyethoxylates by rats and humans. Toxicol Appl Pharm 1980;52:38-44
28. Human repeated insult patch test with various Neodol samples. Shell Chemical Company Report IBT No. F6743, 1969
29. Little AD. Human safety and environmental aspects of major surfactants. Report to the Soap and Detergent Association; 1977
30. Talmadge SS. Environmental and human safety of major surfactants: alcohol ethoxylates and alkylphenol ethoxylates. Boca Raton: Lewis Publishers; 1994
31. Caggiati A, Bergan JJ, Gloviczki P, et al. Nomenclature of the veins of the lower limbs: an international interdisciplinary consensus statement. J Vasc Surg 2002;36:416-422
32. Alos J, Carreno P, Lopez JA, et al. Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. Eur J Vasc Endovasc Surg 2006;31:101-107
33. Rabe E, Otto J, Schliephake D, Pannier F. Efficacy and safety of great saphenous vein sclerotherapy using standardised polidocanol foam (ESAF): a randomised controlled multicentre clinical trial. Eur J Vasc Endovasc Surg 2008;35:238-245
34. Ceulen RP, Bullens-Goessens YI, Pi-VAN DE Venne SJ, et al. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatol Surg 2007;33:276-281
35. Hamel-Desnos C, Ouvry P, Benigni JP, et al. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. The 3/1 Study. Eur J Vasc Endovasc Surg 2007;34:723-729
36. Gibson KD, Regan JD, Shortell C, et al. Proprietary polidocanol endovenous microfoam (PEM) bubble embolization does not cause cerebral injury. Phlebology 2009;24:85
37. Wright DD, Gobin JP, Bradbury AW, et al. Polidocanol microfoam compared with surgery or sclerotherapy in the management of varicose veins in the presence of trunk vein incompetence: European randomized controlled trial. Phlebology 2006;21:180-90
38. Breu FX, Guggenbichler S, Wollmann JC, Second European Consensus Meeting on Foam Sclerotherapy. Duplex ultrasound and efficacy criteria in foam sclerotherapy from the 2nd European Consensus Meeting on Foam Sclerotherapy 2006, Tegernsee, Germany. Vasa 2008;37:90-95
39. Rabe E, Schliephake D, Otto J. Polidocanol, sodium tetradecyl sulphate and placebo for sclerotherapy of C1-varicose veins: a double blind, randomized, controlled clinical trial (EASI-study). Phlebology 2009;24:86
40. Yamaki T, Nozaki M, Sakurai H, et al. Prospective randomized efficacy of ultrasound-guided foam sclerotherapy compared with ultrasound-guided liquid sclerotherapy in the treatment of symptomatic venous malformations. J Vasc Surg 2008;47:578-584
41. Pascarella L, Bergan JJ, Yamada C, Mekenas L. Venous angiomata: treatment with sclerosant foam. Ann Vasc Surg 2005;19:457-464
42. Bergan J, Pascarella L, Mekenas L. Venous disorders: treatment with sclerosant foam. J Cardiovasc Surg 2006;47:9-18
43. Rabe E, Pannier-Fischer F, Gerlach H, et al. Guidelines for sclerotherapy of varicose veins (ICD 10: I83.0, I83.1, I83.2, and I83.9). Dermatol Surg 2004;30:687-693
44. Munavalli GS, Weiss RA. Complications of sclerotherapy. Semin Cutan Med Surg 2007;26:22-28
45. Jia X, Mowatt G, Burr JM, et al. Systematic review of foam sclerotherapy for varicose veins. Br J Surg 2007;94:925-936
46. Duffy D. Small vessel sclerotherapy: an overview. Adv Dermatol 1988;3:221-242
47. Davis LT, Duffy DM. Determination of incidence and risk-factors for postsclerotherapy telangiectatic matting of the lower-extremity: a retrospective analysis. J Derm Surg Oncol 1990;16:327-330
48. Morrison N, Neuhardt DL, Rogers CR, et al. Comparisons of side effects using air and carbon dioxide foam for endovenous chemical ablation. J Vasc Surg 2008;47:830-836
49. Bush RG, Derrick M, Manjoney D. Major neurological events following foam sclerotherapy. Phlebology 2008;23:189-192
50. Forlee MV, Grouden M, Moore DJ, Shanik G. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006;43:162-164
51. Ceulen RP, Sommer A, Vernooy K. Microembolism during foam sclerotherapy of varicose veins. N Engl J Med 2008;358:1525-1526
52. Rush JE, Wright DD. More on microembolism and foam sclerotherapy. N Engl J Med 2008;359:656-657
53. Wright DD, McCollum CN, Tristram S, Rush JE. A single-center pilot study of polidocanol endovenous microfoam (PEM) treatment to evaluate presence and durability of gas emboli using echocardiography. Phlebology 2009;24:87-88
54. Raymond-Martimbeau P. Transient adverse events positively associated with patent foramen ovale after ultrasound-guided foam sclerotherapy. Phlebology 2009;24:114-119
55. Neuhardt D, Morrison N, Rogers C, Salles-Cunha S. Emboli detection in the middle cerebral artery concurrent with treatment of lower extremity superficial venous insufficiency with foam sclerotherapy. Phlebology 2009;24:88-89
56. Rush JE, Wright DD. Neurological and visual symptoms following treatment of the great saphenous vein with two formulations of polidocanol endovenous microfoam (PEM). Phlebology 2009;24:87